Dixon J Brandon, Weiler Michael J
George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, United States; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, United States; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, United States.
Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, United States; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, United States.
Semin Cell Dev Biol. 2015 Feb;38:75-82. doi: 10.1016/j.semcdb.2014.12.003. Epub 2014 Dec 26.
While our understanding of the lymphatic system has improved substantially in the past few decades, the translation of this knowledge into improved healthcare solutions for patients suffering from secondary lymphedema has been severely limited. The challenge facing clinicians is two-fold. First, there is no reliable, affordable, diagnostic capable of detecting the disease before symptoms of the lymphedema develop and the efficacy of treatment options becomes limited. Second, our understanding of the disease pathogenesis, its risk factors, and the underlying physiologic mechanisms is still in its infancy. These two challenges go hand in hand as limited diagnostic options have hindered our ability to understand lymphedema progression, and the lack of known underlying mechanisms involved in the disease prohibits the development of new diagnostic targets. This review serves to discuss the recent developments in clinical and lab research settings of both lymphedema diagnostic technologies and our understanding of the mechanisms driving disease risk and progression. We will show how these two lines of research are synergistically working with the ultimate goal of improving patient outcomes for those suffering from this horrible disease, identifying key areas of further research that are warranted to move the field forward and provide clinical relief for this neglected patient population.
虽然在过去几十年里,我们对淋巴系统的了解有了显著提高,但将这些知识转化为针对继发性淋巴水肿患者的更好医疗解决方案却受到严重限制。临床医生面临的挑战有两方面。首先,在淋巴水肿症状出现且治疗选择的疗效变得有限之前,没有可靠、经济且能够检测出该疾病的诊断方法。其次,我们对该疾病的发病机制、危险因素及潜在生理机制的了解仍处于起步阶段。这两个挑战相互关联,因为有限的诊断选择阻碍了我们了解淋巴水肿进展的能力,而缺乏已知的疾病潜在机制又妨碍了新诊断靶点的开发。本综述旨在讨论淋巴水肿诊断技术在临床和实验室研究方面的最新进展,以及我们对驱动疾病风险和进展机制的理解。我们将展示这两条研究路线如何协同工作,最终目标是改善患有这种可怕疾病患者的治疗效果,确定为推动该领域发展而有必要进一步研究的关键领域,并为这一被忽视的患者群体提供临床缓解。